GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Phase 1
60
about 4.5 years
16+
8 sites in AZ, CA, IL +5
What this study is about
This trial is testing a new treatment, GD2-SADA:177Lu-DOTA complex, for people with certain types of cancer. The treatment involves two separate products delivered as part of a radioimmunotherapy approach. The goal is to evaluate the safety and how well this treatment works in patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take GD2-SADA:177Lu-DOTA Complex
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: To assess cumulative toxicity signals and safety profile (Number and severity of adverse events) following repeated dosing and determine the recommended phase 2 dose (RP2D)
Oncology